STERIS (NYSE:STE – Get Free Report) updated its FY25 earnings guidance on Wednesday. The company provided EPS guidance of $9.05-$9.25 for the period, compared to the consensus EPS estimate of $9.16. STERIS also updated its FY 2025 guidance to 9.050-9.250 EPS.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on STE. Stephens reaffirmed an “overweight” rating and set a $260.00 price objective on shares of STERIS in a research note on Thursday. StockNews.com cut STERIS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 29th. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a report on Wednesday, August 7th. Piper Sandler raised STERIS from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $230.00 to $260.00 in a report on Thursday, October 24th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research note on Friday. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $253.00.
Get Our Latest Stock Analysis on STE
STERIS Stock Up 1.7 %
STERIS (NYSE:STE – Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.11 by $0.03. STERIS had a net margin of 8.02% and a return on equity of 13.91%. The company had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.33 billion. During the same quarter in the prior year, the firm posted $2.03 earnings per share. STERIS’s revenue for the quarter was up 7.3% on a year-over-year basis. Research analysts predict that STERIS will post 9.02 EPS for the current fiscal year.
STERIS Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th will be given a dividend of $0.57 per share. The ex-dividend date of this dividend is Tuesday, November 19th. This represents a $2.28 dividend on an annualized basis and a yield of 1.04%. STERIS’s payout ratio is 52.05%.
Insider Buying and Selling at STERIS
In other news, CFO Michael J. Tokich sold 23,332 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the sale, the chief financial officer now directly owns 42,930 shares of the company’s stock, valued at $10,603,710. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.14% of the stock is currently owned by corporate insiders.
STERIS Company Profile
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
See Also
- Five stocks we like better than STERIS
- What Are Trending Stocks? Trending Stocks Explained
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Roth IRA Calculator: Calculate Your Potential Returns
- MarketBeat Week in Review – 11/4 – 11/8
- Short Selling: How to Short a Stock
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.